Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company BioreclamationIVT has acquired Durham, North Carolina-based Qualyst Transporter Solutions, LLC, (Qualyst) provider of in vitro hepatic models and services that predict the effect of drugs and other compounds on the human liver. Terms of the transaction were not disclosed.
Qualyst (www.qualyst.com) uses a unique cell-based testing approach to predict compound clearance, drug-drug interactions, and toxicity in the human liver, for the pharmaceutical, chemical, consumer products, and cosmetics industries. The Company’s Transporter Certified™ hepatocyte program, now an industry standard, ensures that cells, under defined culture conditions, maintain physiologic transporter uptake and efflux levels which are critical for normal function.